Renalytix Net Worth
Renalytix Net Worth Breakdown | RNLX |
Renalytix Net Worth Analysis
Renalytix's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Renalytix's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Renalytix's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Renalytix's net worth analysis. One common approach is to calculate Renalytix's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Renalytix's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Renalytix's net worth. This approach calculates the present value of Renalytix's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Renalytix's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Renalytix's net worth. This involves comparing Renalytix's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Renalytix's net worth relative to its peers.
Enterprise Value |
|
To determine if Renalytix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Renalytix's net worth research are outlined below:
| Renalytix AI generated a negative expected return over the last 90 days | |
| Renalytix AI has high historical volatility and very poor performance | |
| Renalytix AI has some characteristics of a very speculative penny stock | |
| Renalytix AI has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.29 M. Net Loss for the year was (33.46 M) with profit before overhead, payroll, taxes, and interest of 720 K. | |
| Renalytix AI currently holds about 32.36 M in cash with (30.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Renalytix plc Reports Financial Results for First Quarter of Fis - GuruFocus.com |
Renalytix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Renalytix AI. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Renalytix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 14th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of September 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Know Renalytix's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Renalytix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Renalytix AI backward and forwards among themselves. Renalytix's institutional investor refers to the entity that pools money to purchase Renalytix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Securities, Llc | 2024-06-30 | 24.7 K | Xtx Topco Ltd | 2024-09-30 | 20.2 K | Lpl Financial Corp | 2024-09-30 | 18.4 K | Ewa, Llc | 2024-06-30 | 16.5 K | Jpmorgan Chase & Co | 2024-06-30 | 16.2 K | Baader Bank Inc | 2024-09-30 | 15 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 14.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 12.9 K | Virtu Financial Llc | 2024-06-30 | 12.5 K | Pinnacle Associates Inc | 2024-09-30 | 846.5 K | Stifel Financial Corp | 2024-06-30 | 561 K |
Follow Renalytix's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.55 M.Market Cap |
|
Project Renalytix's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.20) | (4.41) | |
| Return On Capital Employed | 8.40 | 7.74 | |
| Return On Assets | (4.20) | (4.41) | |
| Return On Equity | 4.26 | 4.05 |
When accessing Renalytix's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Renalytix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Renalytix's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Renalytix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Renalytix AI. Check Renalytix's Beneish M Score to see the likelihood of Renalytix's management manipulating its earnings.
Evaluate Renalytix's management efficiency
Renalytix AI has return on total asset (ROA) of (0.9354) % which means that it has lost $0.9354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.7318) %, meaning that it created substantial loss on money invested by shareholders. Renalytix's management efficiency ratios could be used to measure how well Renalytix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -4.41 in 2024. Return On Capital Employed is likely to drop to 7.74 in 2024. At this time, Renalytix's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.3 M in 2024, whereas Total Assets are likely to drop slightly above 7.6 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.07) | (0.07) | |
| Tangible Book Value Per Share | (0.07) | (0.07) | |
| Enterprise Value Over EBITDA | (1.09) | (1.14) | |
| Price Book Value Ratio | (3.46) | (3.63) | |
| Enterprise Value Multiple | (1.09) | (1.14) | |
| Price Fair Value | (3.46) | (3.63) | |
| Enterprise Value | 31 M | 29.4 M |
The decision-making processes within Renalytix are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 14.9699 | Revenue 2.3 M | Quarterly Revenue Growth 0.131 | Revenue Per Share 0.042 | Return On Equity (10.73) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Renalytix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Renalytix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Renalytix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Icahn School Of Medicine At Mount Sinai over three weeks ago Acquisition by Icahn School Of Medicine At Mount Sinai of 13366750 shares of Renalytix at 0.116 subject to Rule 16b-3 | ||
Jung Joel R over three months ago Acquisition by Jung Joel R of 60000 shares of Renalytix at 0.2067 subject to Rule 16b-3 | ||
Jung Joel R over six months ago Insider Trading | ||
Icahn School Of Medicine At Mount Sinai over six months ago Acquisition by Icahn School Of Medicine At Mount Sinai of 9360374 shares of Renalytix at 0.25 subject to Rule 16b-3 | ||
Coste Catherine over a year ago Acquisition by Coste Catherine of 95000 shares of Renalytix subject to Rule 16b-3 | ||
Mclain Thomas H over a year ago Acquisition by Mclain Thomas H of 200000 shares of Renalytix subject to Rule 16b-3 |
Renalytix Earnings per Share Projection vs Actual
Renalytix Corporate Management
| Oliver III | Chief Officer | Profile | |
| Jean Casner | VP Officer | Profile | |
| Baljit Singh | Head Operations | Profile | |
| Howard Doran | Chief Officer | Profile | |
| Salim FCA | Company Secretary | Profile | |
| Fergus Fleming | Chief Officer | Profile | |
| Andria ParksHerrera | VP Marketing | Profile |
Additional Tools for Renalytix Stock Analysis
When running Renalytix's price analysis, check to measure Renalytix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix is operating at the current time. Most of Renalytix's value examination focuses on studying past and present price action to predict the probability of Renalytix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renalytix's price. Additionally, you may evaluate how the addition of Renalytix to your portfolios can decrease your overall portfolio volatility.